Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
Capitol Counsel LLC

2. Address

Address1
700 13th Street NW, 2nd Floor
 Address2
​
City
Washington
 State
DC
 Zip Code
20005
 Country
USA

3. Principal place of business (if different than line 2)

City
​
State
​
Zip Code
​
Country
​
4a. Contact Name b. Telephone Number c. E-mail
​Mrs.
​Allegra M. Han
​2028613200
​ahan@capitolcounsel.com
5. Senate ID#
​313715-51059
7. Client Name Self Check if client is a state or local government or instrumentality
​Baxter Healthcare Corporation
6. House ID#
​393840388
TYPE OF REPORT 8. Year
​2022
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​60,000.00
$5,000 or more $
​
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: Allegra M. Han
 Date
1/19/2023 9:13:40 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Health provisions of the Consolidated Appropriations Act, 2023 (Omnibus) (P.L. No: 117-328) including the Food and Drug Omnibus Reform Act (FDORA) and PREVENT Pandemics Act, and Labor-HHS Appropriations for FY23. H.R. 4346, the CHIPS and Science Act of 2022 (P.L. No: 117-167). Regulatory and reimbursement policy issues relating to healthcare programs, including diabetes and diabetic retinopathy, and Medicare and Medicaid. Monitor drug pricing, medical device, innovation, telemedicine/telehealth, supply chain, and provider issues. Safe mobility issues, including H.Res.1177, Expressing the Sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Martie
Kendrick
​
​
John
Jonas
​
​
Shannon
Finley
​
​
Genny
Beltrone
​
​
Jeffrey
Carroll
​
​
Joseph
Eannello
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Regulatory and reimbursement policy issues relating to healthcare programs, including diabetes and diabetic retinopathy, Medicare and Medicaid, safe mobility issues, drug pricing, medical device, innovation, telemedicine/ telehealth, supply chain, and provider issues.

Monitor issues regarding COVID short and long term challenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding, medical technology and device innovation, supply chain issues, Medicare and Medicaid coverage and reimbursement, artificial intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, diabetes (including diabetic retinopathy), cardiac care, safe mobility standards, safe patient handling, and health infrastructure funding and initiatives. Hospital at Home. Health provisions of the Consolidated Appropriations Act, 2023 (Omnibus) (P.L. No: 117-328) including the Food and Drug Omnibus Reform Act (FDORA) and PREVENT Pandemics Act, and Labor-HHS Appropriations for FY23. H.R. 6833, Making continuing appropriations for fiscal year 2023, and for other purposes (P.L. No: 117-180). H.R. 4346, the CHIPS and Science Act of 2022 (P.L. No: 117-167). Safe mobility issues, including H.Res.1177, Expressing the Sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Martie
Kendrick
​
​
John
Jonas
​
​
Shannon
Finley
​
​
Genny
Beltrone
​
​
Jeffrey
Carroll
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Regulatory and reimbursement policy issues relating to healthcare programs, including Medicare and Medicaid coverage and reimbursement, safe mobility issues, diabetes and diabetic retinopathy, monitor medical device, drug pricing, supply chain, innovation, and provider issues.

Monitor issues regarding COVID short and long term challenges, the Public Health Emergency (PHE), pandemic issues and provider relief funding, medical technology and device innovation, supply chain issues, Medicare and Medicaid coverage and reimbursement, artificial intelligence, health care reform, rural health, telehealth, telemedicine, remote patient monitoring, quality measurement and outcomes, cardiac care, and health infrastructure funding and initiatives. Hospital at Home. Health provisions of the Consolidated Appropriations Act, 2023 (Omnibus) (P.L. No: 117-328) including the Food and Drug Omnibus Reform Act (FDORA) and PREVENT Pandemics Act, and Labor-HHS Appropriations for FY23. H.R. 4346, the CHIPS and Science Act of 2022 (P.L. No: 117-167). Safe mobility issues, including H.Res.1177, Expressing the Sense of the House of Representatives regarding the Centers for Medicare & Medicaid Services developing a mobility metric to guide providers in preventing mobility loss among hospitalized older adults.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Martie
Kendrick
​
​
John
Jonas
​
​
Shannon
Finley
​
​
Genny
Beltrone
​
​
Jeffrey
Carroll
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​
​
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)